Results 11 to 20 of about 787 (175)

Expanding the therapeutic horizons of spesolimab: a review of off-label applications for inflammatory skin diseases

Journal of Dermatological Treatment
Purpose This review aims to outline the crucial role of IL-36 signaling in inflammatory skin diseases and summarize the therapeutic potential of spesolimab.
Hanlin Zhang, Hongzhong Jin, Keyun Tang
exaly   +4 more sources

Trial of Spesolimab for Generalized Pustular Psoriasis [PDF]

New England Journal of Medicine, 2021
Generalized pustular psoriasis (GPP) is a rare, life-threatening, inflammatory skin disease characterized by widespread eruption of sterile pustules. Interleukin-36 signaling is involved in the pathogenesis of this disorder. Spesolimab, a humanized anti-interleukin-36 receptor monoclonal antibody, is being studied for the treatment of GPP flares.In a ...
Hervé, Bachelez, Siew-Eng, Choon, Slaheddine, Marrakchi, A David, Burden, Tsen-Fang, Tsai, Akimichi, Morita, Alexander A, Navarini, Min, Zheng, Jinhua, Xu, Hamida, Turki, Milan J, Anadkat, Sushmita, Rajeswari, Hairui, Hua, Sebastian D, Vulcu, David, Hall, Kay, Tetzlaff, Christian, Thoma, Mark G, Lebwohl   +17 more
core   +8 more sources

Safety and tolerability of spesolimab in patients with ulcerative colitis

Expert Opinion on Drug Safety, 2022
Interleukin (IL)-36 signaling has been shown to be increased in ulcerative colitis (UC). Spesolimab, a novel humanized monoclonal antibody, targets the IL-36 pathway.We report safety, immunogenicity, and efficacy data of intravenous (IV) spesolimab in UC. Study 1: phase II, randomized, placebo-controlled trial (300 mg single dose; 450 mg every 4 weeks [
Marc Ferrante, Peter M Irving, Christian P Selinger, Geert D’Haens, Tanja Kuehbacher, Ursula Seidler, Savion Gropper, Thomas Haeufel, Sebastiano Forgia, Silvio Danese, Jochen Klaus, Brian G. Feagan   +11 more
openaire   +4 more sources

Spesolimab: First Approval

Drugs, 2022
Spesolimab (spesolimab-sbzo; SPEVIGO®) is an interleukin (IL)-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flares in adults.
Hannah A. Blair (13864794)
openaire   +3 more sources

Spesolimab for the Treatment of Generalized Pustular Psoriasis

Drugs, 2023
Generalized pustular psoriasis (GPP) is a rare but severe skin inflammatory disorder characterized by the eruption of widespread sterile neutrophilic pustules, often accompanied by systemic inflammation. Given its life-threatening potential, GPP requires prompt accurate diagnosis and effective treatment, but its rarity and relapsing-remitting nature ...
Diana Bernardo, Diamant Thaçi, Tiago Torres   +2 more
core   +5 more sources

Spesolimab for a child with generalized pustular psoriasis accompanied epilepsy and hyperactivity

Journal of Dermatological Treatment
Objectives To evaluate the therapeutic efficacy and safety of spesolimab in pediatric GPP treatment.Methods We report a 10-year-old male pediatric patient with refractory Generalized Pustular Psoriasis (GPP), comorbid epilepsy, hyperactivity ...
Yudan Wang, Jie Qin, Li Peng, Linli He, Beichen Yang, Mei Yang, Yanyan Feng   +6 more
doaj   +2 more sources

The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab [PDF]

Frontiers in Immunology, 2023
Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disorder characterized by recurrent flares associated with skin erythema, desquamation, and widespread superficial sterile pustules, which may be severe (“lakes of pus”). Systemic
Jason E. Hawkes, Sudha Visvanathan, James G. Krueger   +2 more
doaj   +2 more sources

Treatment of generalized pustular psoriasis with Spesolimab: a case report and literature review

Pifu-xingbing zhenliaoxue zazhi
Objective To evaluate the efficacy and safety of Spesolimab in the treatment of generalized pustular psoriasis(GPP). Methods A 30 years old female with GPP was intravenously given 900 mg of Spesolimab once.
Xiaoqian LIANG, Zexi MI, Yaohan XU, Yongfeng CHEN   +3 more
doaj   +2 more sources

Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare [PDF]

BMJ Open, 2021
Introduction Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening disease characterised by recurrent flares of widespread neutrophilic aseptic skin pustular eruption. Despite the availability of approved biologics for GPP in Japan,
Hamida Turki, Akimichi Morita, Min Zheng, Tsen-Fang Tsai, Siew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, A David Burden, Alexander A Navarini, Jinhua Xu, Sushmita Rajeswari, Hongjie Deng, Kay Tetzlaff, Christian Thoma, Hervé Bachelez   +14 more
doaj   +2 more sources

Case report: Successful treatment with spesolimab of acrodermatitis continua of Hallopeau in an older patient without IL36RN mutations

Frontiers in Immunology
BackgroundAcrodermatitis continua of Hallopeau (ACH) is a rare, sterile pustular psoriasis variant refractory to many conventional treatments. The eruption typically occurs after local trauma or infection; other etiologies include neural, inflammatory ...
Yu-Ling Shi, Jianfeng Zheng, Xuemei Yi
exaly   +3 more sources